Oral fluid cannabinoids in chronic, daily cannabis smokers during sustained, monitored abstinence

Clinical Chemistry

Volumn 57, Issue 8, 2011, Pages 1127-1136

  Lee, Dayong ^a   Milman, Garry ^a   Barnes, Allan J ^a   Goodwin, Robert S ^a   Hirvonen, Jussi ^b   Huestis, Marilyn A ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABIDIOL; CANNABINOL; TETRAHYDROCANNABINOL; TETRAHYDROCANNABINOLIC ACID;

ADULT; ARTICLE; BIOLOGICAL MONITORING; CANNABIS ADDICTION; CANNABIS SMOKING; CLINICAL ARTICLE; HUMAN; INFORMED CONSENT; MALE; MASS FRAGMENTOGRAPHY; QUANTITATIVE ANALYSIS; SMOKING CESSATION;

ADULT; AGED; CANNABIDIOL; CANNABINOIDS; CANNABINOL; CANNABIS; HUMANS; MALE; MARIJUANA ABUSE; MARIJUANA SMOKING; MIDDLE AGED; SALIVA; SUBSTANCE ABUSE DETECTION; TETRAHYDROCANNABINOL; TIME FACTORS; YOUNG ADULT;

CANNABIS;

EID: 79961033088     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2011.164822     Document Type: Article

References (36)

1. United Nations Office on Drugs and Crime. World drug report 2010. http://www.unodc.org/documents/wdr/WDR-2010/World-Drug-Report-2010-lo-res.pdf (Accessed February 2011).
2. Substance Abuse and Mental Health Services Administration. Results from the 2009 National Survey on Drug Use and Health: national findings. http://www.oas.samhsa.gov/NSDUH/2k9NSDUH/2k9ResultsP.pdf (Accessed February 2011).
3. Lacey JH, Kelley-Baker T, Furr-Holden B, Voas RB, Romano E, Ramirez A, et al. 2007 National roadside survey of alcohol and drug use by drivers: drug results. http://www.nhtsa.gov/DOT/NHTSA/Traffic%20Injury%20Control/Articles/ Associated%20Files/811249.pdf (Accessed February 2011).
4. Elkashef A, Vocci F, Huestis M, Haney M, Budney A, Gruber A, et al. Marijuana neurobiology and treatment. Substance Abuse 2008;29:17-29.
5. Huestis MA. Pharmacokinetics and metabolism of the plant cannabinoids, delta-9-tetrahydrocannabinol, cannabidiol and cannabinol. In: Pertwee RG, ed. Handbook of experimental pharmacology. New York: Springer; 2005. p 657-90.
6. Pil K, Verstraete A. Current developments in drug testing in oral fluid. Ther Drug Monit 2008;30:196-202. (Pubitemid 351521647)
7. Bosker WM, Huestis MA. Oral fluid testing for drugs of abuse. Clin Chem 2009;55:1910-31.
8. Cone EJ, Presley L, Lehrer M, Seiter W, Smith M, Kardos KW, et al. Oral fluid testing for drugs of abuse: positive prevalence rates by Intercept immunoassay screening and GC-MS-MS confirmation and suggested cutoff concentrations. J Anal Toxicol 2002;26:541-6. (Pubitemid 35453743)
9. Huestis MA. Human cannabinoid pharmacokinetics. Chem Biodivers 2007;4:1770-804. (Pubitemid 47377203)
10. Moore C, Coulter C, Rana S, Vincent M, Soares J. Analytical procedure for the determination of the marijuana metabolite 11-nor-delta9- tetrahydrocannabinol-9-carboxylic acid in oral fluid specimens. J Anal Toxicol 2006;30:409-12. (Pubitemid 44371480)
11. Day D, Kuntz DJ, Feldman M, Presley L. Detection of THCA in oral fluid by GC-MS-MS. J Anal Toxicol 2006;30:645-50. (Pubitemid 44913015)
12. Milman G, Barnes AJ, Lowe RH, Huestis MA. Simultaneous quantification of cannabinoids and metabolites in oral fluid by two-dimensional gas chromatography mass spectrometry. J Chrom A 2010;1219:1513-21.
13. Davis KH, McDaniel IA, Cadwell IW, Moody PL. Some smoking characteristics of marijuana cigarettes. In: Agurell S, Dewey WL, Willette RE, eds. The cannabinoids: chemical, pharmacologic and therapeutic aspects. Orlando: Academic Press; 1984. p 97-109.
14. Lowe R, Abraham T, Darwin W, Herning R, Cadet J, Huestis M. Extended urinary delta 9 tetrahydrocannabinol excretion in chronic cannabis users precludes use as a biomarker of new drug exposure. Drug Alcohol Depend 2009;105:24-32.
15. Goodwin RS, Darwin WD, Chiang CN, Shih M, Li SH, Huestis MA. Urinary elimination of 11-nor-9-carboxy-Δ9-tetrahydrocannabinol in cannabis users during continuously monitored abstinence. J Anal Toxicol 2008;32:562-6.
16. Karschner E, Schwilke E, Lowe R, Darwin WD, Herning R, Cadet J, et al. Implications of plasma delta 9-tetrahydrocannabinol, 11-hydroxy-THC, and 11-nor-9-carboxy-THC concentrations in chronic cannabis smokers. J Anal Toxicol 2009; 33:469-77.
17. Karschner E, Schwilke E, Lowe R, Darwin W, Pope H, Herning R, et al. Do delta 9-tetrahydrocannabinol concentrations indicate recent use in chronic cannabis users? Addiction 2009;104:2041-8.
18. Huestis MA, Cone EJ. Relationship of delta 9-tetrahydrocannabinold concentrations in oral fluid and plasma after controlled administration of smoked cannabis. J Anal Toxicol 2004;28:394-9. (Pubitemid 39150355)
19. Niedbala RS, Kardos KW, Fritch DF, Kardos S, Fries T, Waga J, et al. Detection of marijuana use by oral fluid and urine analysis following single-dose administration of smoked and oral marijuana. J Anal Toxicol 2001;25:289-303. (Pubitemid 32656280)
20. Johansson E, Noren K, Sjovall J, Halldin MM. Determination of delta-1-tetrahydrocannabinol in human fat biopsies from marijuana users by gas chromatography-mass spectrometry. Biomed Chrom 1989;3:35-8. (Pubitemid 19036470)
21. Drummer OH. Introduction and review of collection techniques and applications of drug testing of oral fluid. Ther Drug Monit 2008;30:203-6. (Pubitemid 351521648)
22. Drummer OH. Review: pharmacokinetics of illicit drugs in oral fluid. Forensic Sci Int 2005; 150:133-42. (Pubitemid 41583215)
23. Bland TM, Haining RL, Tracy TS, Callery PS. CYP2C-catalyzed delta 9-tetrahydrocannabinol metabolism: kinetics, pharmacogenetics and interaction with phenytoin. Biochem Pharmacol 2005;70:1096-103. (Pubitemid 41262085)
24. Goldstein JA. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 2001;52:349-55. (Pubitemid 32939439)
25. Maurer HH, Sauer C, Theobald DS. Toxicokinetics of drugs of abuse: current knowledge of the isoenzymes involved in the human metabolism of tetrahydrocannabinol, cocaine, heroin, morphine, and codeine. Ther Drug Monit 2006;28:447-53. (Pubitemid 44314935)
26. Ramaekers JG, Berghaus G, van Laar M, Drummer OH. Dose related risk of motor vehicle crashes after cannabis use. Drug Alcohol Depend 2004;73:109-19. (Pubitemid 38068347)
27. Wille SMR, Raes E, Lillsunde P, Gunnar T, Laloup M, Samyn N, et al. Relationship between oral fluid and blood concentrations of drugs of abuse in drivers suspected of driving under the influence of drugs. Ther Drug Monit 2009;31:511-9.
28. Toennes S, Ramaekers J, Theunissen E, Moeller M, Kauert G. Pharmacokinetic properties of delta 9-tetrahydrocannabinol in oral fluid of occasional and chronic users. J Anal Toxicol 2010;34:216-21.
29. Choo RE, Huestis MA. Oral fluid as a diagnostic tool. Clin Chem Lab Med 2004;42:1273-87. (Pubitemid 39600330)
30. Niedbala RS, Kardos KW, Fritch DF, Kunsman KP, Blum KA, Newland GA, et al. Passive cannabis smoke exposure and oral fluid testing. II. Two studies of extreme cannabis smoke exposure in a motor vehicle. J Anal Toxicol 2005; 29:607-15. (Pubitemid 41803346)
31. Moore C, Rana S, Coulter C. Simultaneous identification of 2-carboxy-tetrahydrocannabinol, tetrahydrocannabinol, cannabinol and cannabidiol in oral fluid. J Chrom B Analyt Technol Biomed Life Sci 2007;852:459-64. (Pubitemid 46830152)
32. Kauert GF, Ramaekers JG, Schneider E, Moeller MR, Toennes SW. Pharmacokinetic properties of delta 9-tetrahydrocannabinol in serum and oral fluid. J Anal Toxicol 2007;31:288-93. (Pubitemid 46911627)
33. Dietz L, Glaz-Sandberg A, Nguyen H, Skopp G, Mikus G, Aderjan R. The urinary disposition of intravenously administered 11-nor-9-carboxy-delta-9- tetrahydrocannabinol in humans. Ther Drug Monit 2007;29:368-72. (Pubitemid 47262269)
34. Pope HG, Gruber AJ, Hudson JI, Huestis MA, Yurgelun-Todd D. Neuropsychological performance in long-term cannabis users. Arch Gen Psychiatry 2001;58:909-15. (Pubitemid 32937912)
35. Bolla KI, Brown K, Eldreth D, Tate K, Cadet JL. Dose-related neurocognitive effects of marijuana use. Neurology 2002;59:1337-43. (Pubitemid 35285983)
36. Musshoff F, Madea B. Review of biologic matrices (urine, blood, hair) as indicators of recent or ongoing cannabis use. Ther Drug Monit 2006;28: 155-63. (Pubitemid 44314942)